Figure 1 Characterization of these Cap-3M2e
VLPs.
(a) Primary pattern structure of six recombinant Cap-3M2e. (b)
M2e sequence of the human, swine and avian IAV which were used in
challenging experiment. (c) Schematic illustration of Cap-3M2e VLPs
nanovaccine. The VLPs model was derived from the PDB database (3R0R).
(d) SDS-PAGE analysis of these purified Cap-3M2e proteins. Lane M:
molecular weight markers; lane 1: Cap; lane 2: Cap-hsaM2e; lane 3:
Cap-hasM2e; lane 4: Cap-shaM2e; lane 5: Cap-sahM2e; lane 6: Cap-ahsM2e;
lane 7: Cap-ashM2e. (e)
Transmission electron micrograph (TEM) of Cap-3M2e VLPs. The image is
part of the TEM of Cap-ashM2e VLPs. Scale bars = 50 nm. (f) Size
distribution of these Cap-3M2e VLPs (n=5). (g) Zeta potential of these
Cap-3M2e VLPs (n=5).